Back to Cancer Australia's website

Cancer Australia

Select a guideline

Recommendations for Aromatase inhibitors as adjuvant endocrine therapy

Background

Aromatase inhibitors are a class of endocrine drugs that are suitable for post-menopausal women with hormone receptor-positive breast cancer. They are ineffective in pre-menopausal women, including those rendered amenorrheic by chemotherapy who subsequently regain menstrual function.

Published using CeCC Docbook Manager